Abstract Number: 2050 • ACR Convergence 2023
Variability in Vaccination Practices in Children with Rheumatic Diseases: Results of a Rheumatology Provider Childhood Arthritis and Rheumatology Research Alliance (CARRA)-wide Survey
Background/Purpose: Immunocompromised children (ICC), including children with rheumatic diseases receiving immunosuppressive therapies (IST) are at increased risk of morbidity from vaccine-preventable infections. The 2022 American…Abstract Number: 2476 • ACR Convergence 2023
Defining Cutoffs for Disease Activity States in Systemic Juvenile Idiopathic Arthritis Based on the Systemic Juvenile Arthritis Disease Activity Score
Background/Purpose: The systemic Juvenile Arthritis Disease Activity Score (sJADAS) is a composite disease activity (DA) score specifically validated for use in systemic JIA (sJIA), whose…Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…Abstract Number: 0372 • ACR Convergence 2023
Efficacy and Safety of Secukinumab in Juvenile Idiopathic Arthritis: Interim Results from the Extension of the JUNIPERA Trial
Background/Purpose: Secukinumab has demonstrated efficacy and safety in patients with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) categories of juvenile idiopathic arthritis (JIA) for…Abstract Number: 0918 • ACR Convergence 2023
Network Analysis of Genome Sequences Identifies Important Pathways in the Pathogenesis of Childhood-onset Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disorder. The pathogenesis of SLE is not fully understood, but high twin/sibling concordance rates suggest…Abstract Number: 1232 • ACR Convergence 2023
Improvement Across Organ System, Physician and Patient Reported Outcome Measures over a 36-time Period in the Juvenile Systemic Scleroderma Inception Cohort
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1, 000, 000 children. The Juvenile Systemic Scleroderma Inception cohort…Abstract Number: 1252 • ACR Convergence 2023
Physician Global Assessment of Disease Activity in Childhood-Onset Systemic Lupus Erythematosus – Does the Approach Matter?
Background/Purpose: Physician Global Assessment of Disease Activity (PhGA) are commonly used outcome measures in pediatric rheumatology. For childhood-onset systemic lupus erythematosus (cSLE), the traditional visual…Abstract Number: 1705 • ACR Convergence 2023
Reduced DNASE1L3 Activity and Increased Anti-NET Protective Antibodies Contributes to Accumulation of Neutrophil Extracellular Traps in Pediatric SLE Patients
Background/Purpose: Pediatric systemic lupus erythematosus (pSLE) is a multisystemic chronic autoimmune disease with high renal involvement. In SLE, neutrophil extracellular traps (NETs) are considered a…Abstract Number: 2052 • ACR Convergence 2023
Risk Factors for Hospitalization for SARS-CoV-2 in Pediatric Patients with Rheumatic Diseases: A Systematic Review and Meta-analysis
Background/Purpose: Among adults who develop SARS-CoV-2 infection, those with rheumatic diseases (RDs) have similar hospitalization rates compared to those without RDs. Similar comparisons are lacking…Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…Abstract Number: 0352 • ACR Convergence 2023
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…Abstract Number: 1000 • ACR Convergence 2023
Incorporation of Social Drivers of Health Screening into a Structured Healthcare Transition Program for Adolescents and Young Adults with Chronic Rheumatic Disease
Background/Purpose: Social drivers of health (SDoH) such as access to housing and food, may significantly influence safe and timely transition to adult healthcare, yet routine…Abstract Number: 1233 • ACR Convergence 2023
The Pattern of Medication Use Significantly Changed over 36 Months Observation Period. Result from the Juvenile Scleroderma Inception Cohort
Background/Purpose: Juvenile systemic sclerosis (jSSc) is an orphan disease with a prevalence of 3 in 1,000,000 children. Currently no medications are licensed for the treatment…Abstract Number: 1253 • ACR Convergence 2023
The Novel Florida Scoring System: A Machine Learning-Based Stratification of Clinical and Laboratory Features in Children with Suspected Sjögren’s Disease
Background/Purpose: Childhood Sjögren 's disease (cSjD) is a poorly defined systemic autoimmune disorder. Due to the absence of diagnostic criteria, heterogeneous presentations, and the dissimilarity…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 52
- Next Page »